Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose

OBJECTIVE: Dasatinib, a second-generation tyrosine kinase inhibitor, is used for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It reportedly causes pulmonary arterial hypertension (PAH) and the dose-dependent induction of apoptosis in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Kana, Imai, Yasushi, Oh, Iekuni, Ueno, Shuichi, Kanda, Yoshinobu, Kario, Kazuomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424090/
https://www.ncbi.nlm.nih.gov/pubmed/35022343
http://dx.doi.org/10.2169/internalmedicine.8392-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424090/
https://www.ncbi.nlm.nih.gov/pubmed/35022343
http://dx.doi.org/10.2169/internalmedicine.8392-21

Ejemplares similares